Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In schizophrenia, sexual dysfunction is frequent.

2.

Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting

3.

Why breast cancer survivors don't take their medicine, and what can be done about it.

4.

Eliminating the SRC-3 gene in immune cells causes an efficient, long-lasting anti-cancer response.

5.

High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot